Zimbabwe has turned down a substantial US healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years because of Washington's demand for confidential information.
The decision was revealed after a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government spokesman later clarified that the US was demanding access to health data for scientific study and commercial purposes while was not willing to share the benefits from any future treatments.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged continued negotiations to secure a deal acceptable to both sides so the country's critical HIV programme can continue.
Broader Background
This rejection follows a similar case in Kenya, where a high court halted a related deal with the US after concerns were raised about the security of Kenyans' health data.
After returning to office recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government agreements to enhance transparency and responsibility.
According to statements, Sixteen African countries have to date agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy via US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to share its genetic material and health information over an extended period, without any corresponding guarantee of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that provided information," his statement read.
"In essence, our country would provide the raw materials for medical research with no certainty that the resulting innovations would be accessible to our citizens if a new health crisis emerge."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its pursuit of bilateral health agreements were undermining structures previously set up through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This framework is intended to ensure that when a nation provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to ongoing dialogue with our American counterparts on how future collaboration could be structured in a way that honours the independence and interests of both nations."
Medical Community Response
A leading public health body stated it recognised the official position, but recommended that negotiations need to persist since a large portion of the country's HIV programmes depended on external financing.
"In cases where specific concerns exist, including those involving data governance or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," it added.
The situation underscores the ongoing tensions between receiving much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.